Endo (NDOI) Q2 2024 earnings summary

Executive summary

• Emerged from bankruptcy on April 23, 2024, applying fresh start accounting and creating a new reporting entity with a clean balance sheet and modest leverage.

• Issued $2.5 billion in new debt and $500 million in equity, cancelling prior equity and distributing new shares to creditors.

• Leadership transition underway with CEO search; Scott Hirsch appointed interim CEO and Blaise Coleman departing August 29, 2024.

• All legacy litigation claims, including opioid and mesh, were discharged and channeled to trusts as part of the reorganization.

• Focused on growth in branded pharmaceuticals, especially XIAFLEX®, and investments in pipeline and commercial capabilities.

Financial highlights

• Q2 2024 total revenues were $447 million, down 18% year-over-year, mainly due to lower generic and sterile injectables sales and absence of prior-year non-recurring payments.

• Adjusted EBITDA for Q2 2024 was $176 million, down from $243 million in Q2 2023, but exceeded internal expectations.

• Adjusted net income for Q2 2024 was $105 million, compared to $231 million in Q2 2023.

• Net debt to adjusted EBITDA ratio at quarter-end was approximately 3.5x.

• Cash and cash equivalents at June 30, 2024, were $294 million.

Outlook and guidance

• 2024 full-year revenue guidance raised to $1.72–$1.78 billion; adjusted EBITDA guidance increased to $635–$655 million.

• 2025 guidance projects low single-digit revenue growth and mid to high single-digit adjusted EBITDA growth over 2024.

• Branded Pharmaceuticals expected to grow 2–5% in 2025; Sterile Injectables and Generics expected to be flat to slightly down.

• Adjusted gross margin for 2024 expected at 67%; second half margin to be slightly lower due to product mix.